title: Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.
abstract: OBJECTIVE
  To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine.
  
  
  METHODS
  Eight subjects, who received olanzapine for an average duration of 26 months and had gained an average of 13.3 kg bodyweight, participated in a 24-week study in which they received open-label bupropion 150-300 mg/d while continuing olanzapine. The subjects were also provided low-key nutritional counseling. Change in bodyweight was the primary outcome of interest. Changes in fasting blood glucose and lipids were also examined in addition to changes in body composition and bone mineral density.
  
  
  RESULTS
  Seven subjects completed the full 24-week study treatment. In the intent-to-treat sample, mean [SE] bodyweight decreased significantly over time (99.6 [5.9] kg to 96.2 [5.8] kg; F = 4.0; P < 0.001); average weight change for the eight subjects was -3.4 kg. Four of eight subjects lost > or =3% bodyweight. There was a significant reduction in total cholesterol. Weight loss did not have a negative effect on bone mineral density. Side effects were generally mild.
  
  
  CONCLUSIONS
  Bupropion combined with a low-key dietary intervention appeared to be beneficial in reducing olanzapine-associated weight gain in some subjects in this open-label study.
authors.affiliation: Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA. gadde001@mc.duke.edu
authors.forename: Kishore M
authors.initials: KM
authors.lastname: Gadde
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Mariko S
authors.initials: MS
authors.lastname: Foust
mesh_terms: D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D016642:Bupropion / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D004032:Diet; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D014280:Triglycerides / Q000097:blood; D049629:Waist-Hip Ratio; D015430:Weight Gain / Q000187:drug effects*; D015431:Weight Loss / Q000187:drug effects
chemical_list: D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D014280:Triglycerides; D016642:Bupropion; D001569:Benzodiazepines; D002784:Cholesterol; D000077152:Olanzapine